DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

Rhea-AI Summary

DBV Technologies, a clinical-stage biopharmaceutical company, will report its first half 2021 financial results and business updates on August 2, 2021. A conference call and live audio webcast will take place at 5:00 p.m. ET. Viaskin™, the company's investigational platform for immunotherapy, aims to transform the care of food allergic patients, with ongoing trials for Viaskin Peanut. The presentation will be available on their website, along with a replay post-event.

Montrouge, France, July 26, 2021

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, August 2, 2021, at 5:00 p.m. ET to report first half 2021 financial results and provide a corporate update.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50184237.
United States: (866)-939-3921                                                
Canada: (866)-215-5508
United Kingdom: 0808 238 9578                                        
France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Attachment

• PDF Version

FAQ

When will DBVT report its first half 2021 financial results?

DBV Technologies will report its first half 2021 financial results on August 2, 2021.

What is DBV Technologies' main focus?

DBV Technologies focuses on developing the Viaskin™ platform for treating food allergies using epicutaneous immunotherapy.

How can I access the conference call for DBVT's financial results?

The conference call can be accessed via teleconferencing numbers provided in the press release, or through a live audio webcast on their website.